The association of genetic polymorphisms of NUDT15 with the active metabolites and adverse effects of thiopurine drugs in Chinese Han nationality acute lymphocytic leukemia children

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100053342

Enrollment

Unknown

Registered

2021-11-19

Start date

2021-12-01

Completion date

Unknown

Last updated

2022-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lymphoblastic Leukemia (ALL)

Interventions

ALL group:Nil

Eligibility

Sex/Gender

All

Age

3 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed acute lymphoblastic leukemia; 2. Aged 3 to 18 years; 3. Patients receive chemotherapy with CCLG-ALL2008 or CCCG-ALL-2015 regimen; 4. Patients with complete blood and liver and kidney function test results before and after taking 6-MP; 5. Patients have completed 6 cycles of maintenance treatment; 6. Patients with complete information related to this research.

Exclusion criteria

Exclusion criteria: 1. Patients with incomplete clinical and pathological data that cannot be statistically analyzed; 2. Patients without access to blood samples for genetic analysis; 3. Any condition that the investigator considers unsuitable for participation in the clinical study.

Design outcomes

Primary

Measure	Time frame
NUDT15;Concentration of 6-MP;	—

Secondary

Measure	Time frame
Dose of 6-MP;	—

Countries

China

Contacts

Public ContactYu Xiaoxia

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

yxx_xiao@126.com+86 13828479566

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026